Axsome Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business UpdateGlobeNewsWire • 11/06/23
Axsome Therapeutics and the Global Alzheimer's Disease Community Come Together in Raising Support for the Millions Affected by This Illness During Alzheimer's Disease Awareness Month 2023GlobeNewsWire • 11/02/23
Axsome Therapeutics Presents Results of the ACCORD trial of AXS-05 in Alzheimer's Disease Agitation at the Clinical Trials on Alzheimer's Disease (CTAD) 2023 ConferenceGlobeNewsWire • 10/24/23
Axsome Therapeutics to Report Third Quarter 2023 Financial Results on November 6GlobeNewsWire • 10/10/23
Axsome Therapeutics Joins the National Alliance on Mental Illness and Others Advocating for the Importance of Mental Health on Mental Illness Awareness WeekGlobeNewsWire • 10/02/23
Axsome Therapeutics Joins the Global Narcolepsy Community in Raising Awareness on World Narcolepsy DayGlobeNewsWire • 09/21/23
Axsome Therapeutics Highlights Commitment to Innovating Treatments for Mental Health Conditions with Presentations at Psych Congress 2023GlobeNewsWire • 09/07/23
These 3 Stocks Have Underperformed the Market This Year. Is Now the Time to Buy?The Motley Fool • 08/24/23
Axsome Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business UpdateGlobeNewsWire • 08/07/23
Axsome Therapeutics to Report Second Quarter 2023 Financial Results on August 7GlobeNewsWire • 07/12/23